Lower Back and Sciatica Pain
BSC Envision
Study Title
RELIEF Study – ENVISION Cohort
Purpose
The objective of the study is to characterize the relationship between select objective metrics and clinical outcomes in chronic pain patients treated with Boston Scientific commercially approved neurostimulation systems and may use observed relationships to make recommendations.
Basic Eligibility Criteria
- 18 years of age and older
- Planning to receive or has received a commercially approved Boston Scientific neurostimulation system for pain per local directions for use.
Study Site Locations
Springhill 2 and Ayers
Contact
Regina Knudsen, 352-273-6786, rknudsen@anest.ufl.edu
BSC RAPID RFA
Study Title
Radiofrequency (RF) Ablation Prospective Outcomes Study
Purpose
To compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems in the treatment of patients diagnosed with pain
Basic Eligibility Criteria
- 18 years of age or older
- Being treated with Boston Radio Frequency Ablation for pain
Study Site Location
Springhill 2 and Ayers
Contact
Amanda Slater, 352-273-8952, aslater@anest.ufl.edu
SI Stem Cell Injection
Study Title
A phase 1, open label dose-ranging study to assess the safety, tolerability, preliminary efficacy, and dose effect of CFL001 cord blood product in patients with symptomatic sacroiliac joint syndrome.
Purpose
The overall objective is to evaluate the safety and potential efficacy effect of specific type of umbilical cord blood product (CFL001).
Basic Eligibility Criteria
- 18 to 90 years old
- SI joint syndrome
- Have tried and failed other conservative pain therapies (i.e. Tylenol, NSAIDs, Tramadol, etc.)
Study Site Location(s)
Springhill 2 and Ayers
Contact
Amy Gunnett, RN, CCRC, 352-273-8911, agunnett@anest.ufl.edu
Cancer Pain
Sorrento
Study Title
A multicenter phase 2 study to assess the safety and efficacy of epidural resiniferatoxin for the treatment of intractable pain associated with advanced cancer.
Purpose
- To assess the safety of epidural RTX compared to the control groups
- Short-term treatment-emergent AEs (TEAEs) during the 6- and 24-hours post RTX administration
- Long-term TEAEs, particularly AEs of special interest (AESIs)
- Neurologic disorders in the area below the injection target
- Bladder incontinence
Basic Eligibility Criteria
- 18 years of age or older
- Have advanced or metastatic cancer
- Have pain that is “intractable” in that it has not responded to standard therapies
Study Site Location(s)
Springhill 2 and Florida Surgical Center
Contact
Amy Gunnett, RN, CCRC, 352-273-8911, agunnett@anest.ufl.edu
Knee Pain
SKOAP
Study Title
A Sequenced Strategy for Improving Outcomes in People with Knee Osteoarthritis Pain (SKOAP)
Purpose
- To determine the extent to which duloxetine and the combined effects of painTrainer and duloxetine improve pain and function in participants with KOA and/or
- Among those interested in additional treatment, including those following conservative treatment and those inappropriate for conservative care, determine whether nonsurgical procedural interventions improve pain and function.
Basic Eligibility Criteria
- 18 years of age to 80 years of age
- Diagnosis of knee osteoarthritis
- Have insurance or willing to pay out of pocket
- Have access to reliable internet
Study Site Locations
Springhill 2 and Ayers
Contact
Amanda Slater, 352-273-8952, aslater@anest.ufl.edu
Study Website
EN20-01 Centrexion
Study Title
EN20-01: A 24-Week study to evaluate the safety and efficiency of CNTX-6970 in subjects with moderate to severe knee osteoarthritis pain.
Purpose
To evaluate the safety and effectiveness of the drug CNTX-6970 on the treatment of knee osteoarthritis.
Basic Eligibility Criteria
- 40 years of age to 80 years of age
- Osteoarthritis of the knee
- No current use of pain medication, other than Tylenol
Study Site Location
Springhill 2
Contact
Brandi Lattinville, 352-294-8346, blattinville@anest.ufl.edu
Pelvic Pain
Abbott REALITY (pelvic pain only)
Study Title
Long-Term Real-World Outcomes Study on Patients Implanted with a Neurostimulator
Purpose
To capture long-term, real-world, safety and effectiveness data on Abbott’s market released neurostimulator systems.
Basic Eligibility Criteria
- 18 years of age and older
- Get a SCS or DRG implant
Study Site Locations
Springhill 2 and Ayers
Contact
Amanda Slater, 352-273-8952, aslater@anest.ufl.edu
Diabetic Neuropathy
EN21-01 Diabetic Peripheral Neuropathy
Contact
Brandi Lattinville, 352-294-8346, blattinville@anest.ufl.edu
EN21-02 Diabetic Peripheral Neuropathy
Contact
Brandi Lattinville, 352-294-8346, blattinville@anest.ufl.edu